PDCD1 and renal carcinoma: In particular, studies involving the use of monoclonal antibodies directed against the PD-1 receptor and its ligand PD-L1 have shown promising response rates, leading to FDA approval of PD-1 drugs for advanced melanoma, lung and renal cancer [31, 32].